Brussels, Belgium, June 23, 2015

Merodis, a corporate finance consulting firm serving small and medium sized companies or larger companies pursuing similar sized opportunities, is proud to announce that it advised the selling shareholders of Labima in its sale to Vemedia.

Labima (http://www.labima.com/), a Brussels-based pharmaceutical company, occupies a 700 m² GMP-approved plant which it uses to provide contract manufacturing services and to produce its own OTC drugs. Over the last years, the company’s growth has been primarily driven by the success of its R-Calm Dimenhydrinate® drug in the anti-nausea, vomitting and travel sickness segments. Labima was a family-owned company backed by minority shareholder finance.brussels/group SRIB (www.finance.brussels).

Vemedia (www.vemedia.com) is a fast growing consumer health company, marketing leading self-medication brands primarily in selected Western European countries. Vemedia is headquartered in Diemen, the Netherlands and enjoys the #1 position amongst others in its home market. Vemedia has its own operations in 8 countries and employs over 240 people. Vemedia manufactures the majority of its products in its GMP-licenced manufacturing facility, specialized in the production of (film-coated) tablets, sachets and capsules in bottles and blisterpacks.

For more information, please contact:

Rodolphe Blondiau
rbl@merodis.com, +32 488 81 45 07
Dirk Marckx
dma@merodis.com, +32 495 38 17 81